Smoking and papillomavirus DNA in patients with p16-positive N3 oropharyngeal squamous cell carcinoma.
Cohort Studies
DNA, Viral
/ analysis
Databases, Factual
Disease-Free Survival
Female
Genes, p16
Head and Neck Neoplasms
/ mortality
Humans
Kaplan-Meier Estimate
Male
Neoplasm Invasiveness
/ pathology
Neoplasm Staging
Oropharyngeal Neoplasms
/ mortality
Papillomaviridae
/ genetics
Prognosis
Proportional Hazards Models
Retrospective Studies
Risk Assessment
Smoking
/ adverse effects
Squamous Cell Carcinoma of Head and Neck
/ mortality
Survival Analysis
N3
human papillomavirus
oropharyngeal neoplasms
p16 immunohistochemistry
smoking history
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
06
02
2018
revised:
20
08
2018
accepted:
05
10
2018
pubmed:
16
12
2018
medline:
10
10
2020
entrez:
16
12
2018
Statut:
ppublish
Résumé
We investigated the survival of patients with a p16-positive N3 oropharyngeal squamous cell carcinoma (OPSCC) and the prognostic significance of patient, tumor, and treatment characteristics. We retrospectively reviewed the data of patients treated at our Cancer Center for a p16-positive N3 OPSCC between 2003 and 2016. End points were overall survival (OS) and progression-free survival (PFS). A total of 29 patients were included. The 5-year OS and PFS were 67.5% and 59.1%, respectively. Smoking history above 10 pack-years and the absence of human papillomavirus DNA were associated with worse OS (P = .02 and P = .03, respectively) and PFS (P = .02 and P = .02, respectively). Induction chemotherapy or radical neck dissection were not associated with different treatment outcomes. Patients with an N3 p16-positive oropharyngeal cancer in our series had a 5-year OS rate of 67.5%. Smoking history and viral DNA were prognostic factors associated with survival.
Sections du résumé
BACKGROUND
We investigated the survival of patients with a p16-positive N3 oropharyngeal squamous cell carcinoma (OPSCC) and the prognostic significance of patient, tumor, and treatment characteristics.
METHODS
We retrospectively reviewed the data of patients treated at our Cancer Center for a p16-positive N3 OPSCC between 2003 and 2016. End points were overall survival (OS) and progression-free survival (PFS).
RESULTS
A total of 29 patients were included. The 5-year OS and PFS were 67.5% and 59.1%, respectively. Smoking history above 10 pack-years and the absence of human papillomavirus DNA were associated with worse OS (P = .02 and P = .03, respectively) and PFS (P = .02 and P = .02, respectively). Induction chemotherapy or radical neck dissection were not associated with different treatment outcomes.
CONCLUSION
Patients with an N3 p16-positive oropharyngeal cancer in our series had a 5-year OS rate of 67.5%. Smoking history and viral DNA were prognostic factors associated with survival.
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1039-1045Informations de copyright
© 2018 Wiley Periodicals, Inc.